Correlation of blood glucose, serum chemerin and insulin resistance with NAFLD in patients with type 2 diabetes mellitus

Zhang,Zhengjun; Wang,Jijun; Wang,Hongmei

doi:10.3892/etm.2018.5753

Correlation of blood glucose, serum chemerin and insulin resistance with NAFLD in patients with type 2 diabetes mellitus

Authors:
- Zhengjun Zhang
- Jijun Wang
- Hongmei Wang
View Affiliations

Affiliations: Department of Endocrinology, The Affiliated Hospital of Jining Medical University, Jining, Shandong 272000, P.R. China, Department of Internal Medicine, Jining Municipal Government Hospital, Jining, Shandong 272100, P.R. China
Published online on: January 16, 2018 https://doi.org/10.3892/etm.2018.5753
Pages: 2936-2940
Copyright: © Zhang et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Non-alcoholic fatty liver disease (NAFLD) is a form of clinical syndrome characterized by the fatty degeneration in liver histology and should be further investigated. The aim of the study was to investigate the effects of blood glucose, serum chemerin and insulin resistance on non‑alcoholic fatty liver disease (NAFLD) in patients with type 2 diabetes mellitus to provide a basis for the prevention and treatment thereof. In total, 300 patients with type 2 diabetes mellitus treated and admitted into the Endocrinology Department of our hospital from June 2015 to June 2017 were enrolled and divided into the simple type 2 diabetes mellitus (group A) and concurrent NAFLD (group B) groups. The sex, age, body mass index (BMI), blood pressure, blood biochemical indexes and chemerin level were compared between the two groups. The patients in group B were further divided into the mild fatty liver (group B1), moderate fatty liver (group B2) and severe fatty liver (group B3) groups. The sex, age, BMI blood pressure, blood biochemical indexes and chemerin level were also compared among the three groups. Finally, the risk factors of type 2 diabetes mellitus complicated by NAFLD were analyzed via logistic regression. The BMI, fasting plasma glucose (FPG), 2 h post-prandial plasma glucose (2hPG), triglyceride (TG), total cholesterol (TC), low-density lipoprotein cholesterol (LDL-c), alanine aminotransferase (ALT), fasting insulin (FINS), homeostasis model assessment of insulin resistance (HOMA-IR) and HOMA-β indexes and serum chemerin level in group B were significantly higher than those in group A (P<0.05 or P<0.01). Notably, the aggravation of NAFLD, the aforementioned indexes were obviously increased (P<0.05 or P<0.01). The regression analysis revealed that BMI, FPG, TC, LDL-c, FINS, HOMA-IR and chemerin were risk factors of concurrent NAFLD. Thus, type 2 diabetes mellitus complicated by NAFLD is closely associated with severe glucose-lipid metabolism disorder and insulin resistance, and BMI, FPG, TC, LDL-c, FINS, HOMA-IR and chemerin constitute risk factors of concurrent NAFLD.

View Figures

View References

1	Fruci B, Giuliano S, Mazza A, Malaguarnera R and Belfiore A: Nonalcoholic fatty liver: A possible new target for type 2 diabetes prevention and treatment. Int J Mol Sci. 14:22933–22966. 2013. View Article : Google Scholar : PubMed/NCBI
2	Mavrogiannaki AN and Migdalis IN: Nonalcoholic fatty liver disease, diabetes mellitus and cardiovascular disease: Newer data. Int J Endocrino. 2013:4506392013. View Article : Google Scholar
3	Targher G, Bertolini L, Poli F, Rodella S, Scala L, Tessari R, Zenari L and Falezza G: Nonalcoholic fatty liver disease and risk of future cardiovascular events among type 2 diabetic patients. Diabetes. 54:3541–3546. 2005. View Article : Google Scholar : PubMed/NCBI
4	Stepanova M, Rafiq N and Younossi ZM: Components of metabolic syndrome are independent predictors of mortality in patients with chronic liver disease: A population-based study. Gut. 59:1410–1415. 2010. View Article : Google Scholar : PubMed/NCBI
5	Bozaoglu K, Bolton K, McMillan J, Zimmet P, Jowett J, Collier G, Walder K and Segal D: Chemerin is a novel adipokine associated with obesity and metabolic syndrome. Endocrinology. 148:4687–4694. 2007. View Article : Google Scholar : PubMed/NCBI
6	Chu SH, Lee MK, Ahn KY, Im JA, Park MS, Lee DC, Jeon JY and Lee JW: Chemerin and adiponectin contribute reciprocally to metabolic syndrome. PLoS One. 7:e347102012. View Article : Google Scholar : PubMed/NCBI
7	Alberti KG and Zimmet PZ: Definition, diagnosis and classification of diabetes mellitus and its complications. Part. 1:diagnosis and classification of diabetes mellitus provisional report of a WHO consultation. Diabet Med 15: 539–553. 1998.
8	Macavei B, Baban A and Dumitrascu DL: Psychological factors associated with NAFLD/NASH: A systematic review. Eur Rev Med Pharmacol Sci. 20:5081–5097. 2016.PubMed/NCBI
9	Amarapurkar DN, Hashimoto E, Lesmana LA, Sollano JD, Chen PJ and Goh KL; Asia-Pacific Working Party on NAFLD, : How common is non-alcoholic fatty liver disease in the Asia-Pacific region and are there local differences? J Gastroenterol Hepatol. 22:788–793. 2007. View Article : Google Scholar : PubMed/NCBI
10	Day CP and James OF: Steatohepatitis: A tale of two ‘hits’? Gastroenterology. 114:842–845. 1998. View Article : Google Scholar : PubMed/NCBI
11	Kim CH and Younossi ZM: Nonalcoholic fatty liver disease: A manifestation of the metabolic syndrome. Cleve Clin J Med. 75:721–728. 2008. View Article : Google Scholar : PubMed/NCBI
12	Moreno Sánchez D: Pathogenesis of primary nonalcoholic fatty liver disease. Med Clin (Barc). 124:668–677. 2005.(In Spanish). PubMed/NCBI
13	Chitturi S, Wong VW and Farrell G: Nonalcoholic fatty liver in Asia: Firmly entrenched and rapidly gaining ground. J Gastroenterol Hepatol. 26 Suppl 1:163–172. 2011. View Article : Google Scholar : PubMed/NCBI
14	Pacifico L, Nobili V, Anania C, Verdecchia P and Chiesa C: Pediatric nonalcoholic fatty liver disease, metabolic syndrome and cardiovascular risk. World J Gastroenterol. 17:3082–3091. 2011.PubMed/NCBI
15	Targher G, Valbusa F, Bonapace S, Bertolini L, Zenari L, Rodella S, Zoppini G, Mantovani W, Barbieri E and Byrne CD: Non-alcoholic fatty liver disease is associated with an increased incidence of atrial fibrillation in patients with type 2 diabetes. PLoS One. 8:e571832013. View Article : Google Scholar : PubMed/NCBI
16	Targher G, Bertolini L, Rodella S, Zoppini G, Lippi G, Day C and Muggeo M: Non-alcoholic fatty liver disease is independently associated with an increased prevalence of chronic kidney disease and proliferative/laser-treated retinopathy in type 2 diabetic patients. Diabetologia. 51:444–450. 2008. View Article : Google Scholar : PubMed/NCBI
17	Jorgensen RA: Nonalcoholic fatty liver disease. Gastroenterol Nurs. 26:150–155. 2003. View Article : Google Scholar : PubMed/NCBI
18	Azam G, Alam S, Hasan SKMN, Alam SMNE, Kabir J and Alam AKMK: Insulin resistance in nonalcoholic fatty liver disease. Experience from Bangladesh. Bangladesh Critical Care Journal. 4:862016.doi: org/10.3329/bccj.v4i2.30022. View Article : Google Scholar
19	Targher G, Bertolini L, Padovani R, Rodella S, Tessari R, Zenari L, Day C and Arcaro G: Prevalence of nonalcoholic fatty liver disease and its association with cardiovascular disease among type 2 diabetic patients. Diabetes Care. 30:1212–1218. 2007. View Article : Google Scholar : PubMed/NCBI
20	Kelley DE, McKolanis TM, Hegazi RA, Kuller LH and Kalhan SC: Fatty liver in type 2 diabetes mellitus: Relation to regional adiposity, fatty acids, and insulin resistance. Am J Physiol Endocrinol Metab. 285:E906–E916. 2003. View Article : Google Scholar : PubMed/NCBI
21	Peng L, Yu Y, Liu J, Li S, He H, Cheng N and Ye RD: The chemerin receptor CMKLR1 is a functional receptor for amyloid-β peptide. J Alzheimers Dis. 43:227–242. 2015.PubMed/NCBI
22	Lehrke M, Becker A, Greif M, Stark R, Laubender RP, von Ziegler F, Lebherz C, Tittus J, Reiser M, Becker C, et al: Chemerin is associated with markers of inflammation and components of the metabolic syndrome but does not predict coronary atherosclerosis. Eur J Endocrinol. 161:339–344. 2009. View Article : Google Scholar : PubMed/NCBI
23	Zhuang X, Sun F, Li L, Jiang D, Li X, Sun A, Pan Z, Lou N, Zhang L and Lou F: Therapeutic effect of metformin on chemerin in non-obese patients with non-alcoholic fatty liver disease (NAFLD). Clin Lab. 61:1409–1414. 2015.PubMed/NCBI
24	Stejskal D, Karpisek M, Hanulova Z and Svestak M: Chemerin is an independent marker of the metabolic syndrome in a Caucasian population - a pilot study. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub. 152:217–221. 2008. View Article : Google Scholar : PubMed/NCBI